Flavokawain BFlavokawain B
MedChemExpress (MCE)
HY-N2132
1775-97-9
Flavokavain B
99.99%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of PARP. Flavokawain B down-regulates Bcl-2 with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation.
Flavokawain B (1-5 µg/mL, 18-24 h) inhibits human brain endothelial cell (HUVEC) migration and tube formation[1]. Flavokawain B (1.25-20 µg/mL, 18 h) induces proliferation inhibition and apoptosis in multiple B-cell lymphoma cell lines through downregulating the PI3K/Akt axis[3]. Flavokawain B (5-40 µM, 1 h) shows anti-inflammatory activities, with inhibiting production of NO and PGE2 in LPS-induced RAW 264.7 cells[4]. Flavokawain B (17.6-70.4 μM, 24 h) results in apoptosis of KB cells, evidenced by loss of cell viability, profound morphological changes, genomic DNA fragmentation and sub-G1 phase accumulation[5]. Flavokawain B (2.5-7.5 µg/mL, 24 h) induces apoptosis in synovial sarcoma cell lines[6]. Flavokawain B (2.5-7.5 µg/mL, 24 h) inhibits growth of human osteosarcoma cells (143B and saos-2) through G2/M cell cycle arrest and apoptosis[7]. Flavokawain B (1.25-10 μg/mL, 24 h) induces apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway[8]. Flavokawain B (2.5-5 μg/mL, 24 h) exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line SK-LMS-1 and ECC-1[9].
Flavokawain B (1-2.5 µg/mL, 24 h) suppresses angiogenesis in a zebrafish model[1]. Flavokawain B (50-200 mg/kg, i.p.) shows anti-inflammatory activities in LPS-induced mice[4]. Flavokawain B (0.35-0.75 mg/kg, i.p., every 2 days, 27 days) significantly inhibits in vivo growth of human KB cell-derived tumor xenografts in nude mice[5]. Flavokawain B (20-40 mg/kg, p.o., 7 days) inhibits NF-κB inflammatory signaling pathway activation in colitis mice by targeting TLR2[10]. Flavokawain B (25 mg/kg, p.o., daily for a week) induces GSH-sensitive oxidative stress in mice through modulation of IKK/NF-κB and MAPK signaling pathways[11]. Flavokawain B (10-20 mg/kg, i.g., 3 consecutive days) alleviates LPS-induced acute lung injury in mice via targeting myeloid differentiation factor 2[12]. Flavokawain B (25 mg/kg, i.p., twice-a-week for 2 weeks) in combination with Cisplatin (HY-17394)/Gemcitabine (HY-17026) significantly inhibits tumor growth in a xenograft mouse (SNU-478 cells) model[13].
| | | |
| | | | | |
[1]. Rossette MC, et al. The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phytother Res. 2017 Oct
31(10):1607-1613. [Content Brief]
[2]. Li X, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Cell Commun Signal. 2019 Mar 18
17(1):25. [Content Brief]
[3]. Zhao M, et al. The kava chalcone flavokawain B exerts inhibitory activity and synergizes with BCL-2 inhibition in malignant B-cell lymphoma. Phytomedicine. 2023 Nov
120:155074. [Content Brief]
[4]. Lin CT, et al. Anti-inflammatory activity of Flavokawain B from Alpinia pricei Hayata. J Agric Food Chem. 2009 Jul 22
57(14):6060-5. [Content Brief]
[5]. Lin E, et al. Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem. 2012 Apr
23(4):368-78. [Content Brief]
[6]. Sakai T, et al. Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines. J Orthop Res. 2012 Jul
30(7):1045-50. [Content Brief]
[7]. Ji T, et al. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer. 2013 Jun 10
12:55. [Content Brief]
[8]. Hseu YC, et al. The chalcone flavokawain B induces G2/M cell-cycle arrest and apoptosis in human oral carcinoma HSC-3 cells through the intracellular ROS generation and downregulation of the Akt/p38 MAPK signaling pathway. J Agric Food Chem. 2012 Mar 7
60(9):2385-97. [Content Brief]
[9]. Eskander RN, et al. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug
38(8):1086-94. [Content Brief]
[10]. Chen Y, et al. Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in inflammatory bowel disease by targeting TLR2. Toxicol Appl Pharmacol. 2024 May
486:116922. [Content Brief]
[11]. Zhou P, et al. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J. 2010 Dec
24(12):4722-32. [Content Brief]
[12]. Luo W, et al. Flavokawain B alleviates LPS-induced acute lung injury via targeting myeloid differentiation factor 2. Acta Pharmacol Sin. 2022 Jul
43(7):1758-1768. [Content Brief]
[13]. Son JH, et al. Flavokawain B Inhibits Growth of Cholangiocarcinoma Cells by Suppressing the Akt Pathway. In Vivo. 2023 May-Jun
37(3):1077-1084. [Content Brief]
